Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), and Kurma Partners, a Paris, France and Munich, Germany-based venture capital firm in healthcare and biotechnology, announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.
Under the terms of the multi-year agreement, Samsung Biologics will provide customizable chemistry, manufacturing, and control (CMC) development services for Kurma Partners’ portfolio companies to streamline the gene to Investigational New Drug (IND) process, de-risk uncertainties in CMC, and accelerate the lead candidate selection through entry into first-in-human studies with seamless transitions along further clinical development.
The portfolio companies will be able to leverage Samsung Biologics’ state-of-the-art facilities, proprietary technology platforms, and CMC-related expertise.
Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Its facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize its operational efficiency and expand capabilities in response to growing biomanufacturing demands, Samsung Biologics recently completed Bio Campus I with Plant 4 offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025, adding 180KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe.
Founded in July 2009, Kurma Partners is a European venture capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital, in particular through its funds Kurma Biofund I, II, III, Kurma Diagnostics and Kurma Diagnostics 2 and its recent Kurma Growth Opportunities Fund. Kurma Partners is part of the Eurazeo Group.